Optherion Overview

Optherion, Inc. is a biotechnology company that is developing diagnostic and disease-modifying therapeutics for the management and treatment of early-stage age-related macular degeneration (AMD), dense deposit disease (DDD, also referred to as membranoproliferative glomerulonephritis [MPGN II]), atypical hemolytic uremic syndrome (aHUS), and other chronic diseases involving the alternative...More»

Optherion, Inc. is a biotechnology company that is developing diagnostic and disease-modifying therapeutics for the management and treatment of early-stage age-related macular degeneration (AMD), dense deposit disease (DDD, also referred to as membranoproliferative glomerulonephritis [MPGN II]), atypical hemolytic uremic syndrome (aHUS), and other chronic diseases involving the alternative complement cascade.

Optherion’s intellectual properties are based on recent scientific discoveries linking specific genes to AMD and various renal diseases. AMD is the leading cause of blindness in people over 60 in the developed world. It is estimated that there are 15-20 million people with AMD in the U.S. and more than 50 million worldwide. DDD and aHUS are rare renal diseases that most commonly occur in young people and frequently lead to end-stage renal disease.«Less